A group of Ciphergen shareholders are drafting a no-confidence letter stating that they are dissatisfied with the company’s progress and share values, and that they seek to replace top management, ProteoMonitor has learned.
The shareholders are taking these steps after Ciphergen reported last week a 12.7-percent fall-off in total revenue during the fourth quarter of 2004.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
